These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193651 [TBL] [Abstract][Full Text] [Related]
27. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. Lepak AJ; Zhao M; Andes DR Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059 [TBL] [Abstract][Full Text] [Related]
29. Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712210 [TBL] [Abstract][Full Text] [Related]
30. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia. Lee YR; Jacobs KL Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486 [TBL] [Abstract][Full Text] [Related]
31. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic. Covvey JR; Guarascio AJ J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035 [TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Andes D; Craig WA Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855 [TBL] [Abstract][Full Text] [Related]
33. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. van Os W; Zeitlinger M J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805 [TBL] [Abstract][Full Text] [Related]
34. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin. Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694 [TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. So W; Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2015 Aug; 59(8):4956-61. PubMed ID: 26055376 [TBL] [Abstract][Full Text] [Related]
36. Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia. Felix TM; Karpa K Am Fam Physician; 2020 Sep; 102(6):373-374. PubMed ID: 32931220 [No Abstract] [Full Text] [Related]
37. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Andes D; Craig WA Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504 [TBL] [Abstract][Full Text] [Related]
38. Zhou YF; Liu P; Dai SH; Sun J; Liu YH; Liao XP Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928734 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia. Perry W; Golan Y Future Microbiol; 2019 Jul; 14():927-939. PubMed ID: 31333062 [TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo pharmacokinetic/pharmacodynamic activity of clofoctol. Scaglione F; Dugnani S; Lucini V; Pannacci M; Paraboni L J Chemother; 2012 Aug; 24(4):201-6. PubMed ID: 23040683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]